Icon Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Icon Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-29,700	Closed	-$1.84M	–	164
2022 Q3	$1.84M	Buy	+29,700	New	+$2.08M	0.5%	76
2017 Q2	–	Sell	-62,300	Closed	-$921K	–	435
2017 Q1	$921K	Buy	62,300 +46,700	+299%	+$756K	0.06%	286
2016 Q4	$252K	Sell	15,600 -19,400	-55%	-$352K	0.02%	392
2016 Q3	$635K	Buy	+35,000	New	+$684K	0.04%	343

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Icon Advisers's HZNP Position: Q4 2022 in Review

Icon Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 29,700 shares — an estimated $1.84M sold.

Icon Advisers first reported a position in HZNP in Q3 2016 and held it in 4 quarters. The position peaked at $1.84M in Q3 2022. 613 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Icon Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Icon Advisers sold 29,700 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $1.84M.
Icon Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 4 quarters.
Icon Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.84M in Q3 2022.
613 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Icon Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.